These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 15987229)

  • 1. Costs and medical care consequences associated with the diagnosis of peripheral arterial disease.
    Migliaccio-Walle K; Caro JJ; Ishak KJ; O'Brien JA
    Pharmacoeconomics; 2005; 23(7):733-42. PubMed ID: 15987229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health care resources and costs for treating peripheral artery disease in a managed care population: results from analysis of administrative claims data.
    Margolis J; Barron JJ; Grochulski WD
    J Manag Care Pharm; 2005; 11(9):727-34. PubMed ID: 16300416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term resource use patterns and healthcare costs after myocardial infarction in a clinical practice setting: results from a contemporary nationwide registry study.
    Janzon M; Henriksson M; Hasvold P; Hjelm H; Thuresson M; Jernberg T
    Eur Heart J Qual Care Clin Outcomes; 2016 Oct; 2(4):291-298. PubMed ID: 29474723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of cardiovascular disease on health care economic burden and resource utilization: a retrospective cohort study in adults in the United States with type 2 diabetes with or without stroke, myocardial infarction, and peripheral arterial disease.
    King A; Rajpura J; Liang Y; Paprocki Y; Uzoigwe C
    Curr Med Res Opin; 2022 Nov; 38(11):1831-1840. PubMed ID: 36134459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Healthcare costs with tiotropium plus usual care versus usual care alone following 1 year of treatment in patients with chronic obstructive pulmonary disorder (COPD).
    Friedman M; Menjoge SS; Anton SF; Kesten S
    Pharmacoeconomics; 2004; 22(11):741-9. PubMed ID: 15250751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The economic implications of treating atherothrombotic disease in Australia, from the government perspective.
    Ademi Z; Liew D; Hollingsworth B; Wolfe R; Steg GP; Bhatt DL; Reid CM;
    Clin Ther; 2010 Jan; 32(1):119-32; discussion 106-7. PubMed ID: 20171418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and economic burden in patients with diagnosis of peripheral arterial disease in a claims database in Japan.
    Hosaka A; Miyata T; Onishi Y; Liao L; Zhang Q
    Clin Ther; 2014 Aug; 36(8):1223-30, 1230.e1-4. PubMed ID: 25012730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization.
    Bullano MF; Willey V; Hauch O; Wygant G; Spyropoulos AC; Hoffman L
    J Manag Care Pharm; 2005 Oct; 11(8):663-73. PubMed ID: 16194130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the consequences associated with diffuse vascular disease history in patients diagnosed with peripheral arterial disease: estimates from Saskatchewan health data.
    Migliaccio-Walle K; Stokes M; Proskorovsky I; Popovici-Toma D; El-Hadi W
    BMC Cardiovasc Disord; 2010 Sep; 10():40. PubMed ID: 20813057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The time course of subsequent hospitalizations and associated costs in survivors of an ischemic stroke in Canada.
    Caro JJ; Migliaccio-Walle K; Ishak KJ; Proskorovsky I; O'Brien JA
    BMC Health Serv Res; 2006 Aug; 6():99. PubMed ID: 16907982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and economic burden associated with cardiovascular events among patients with hyperlipidemia: a retrospective cohort study.
    Fox KM; Wang L; Gandra SR; Quek RGW; Li L; Baser O
    BMC Cardiovasc Disord; 2016 Jan; 16():13. PubMed ID: 26769473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-year vascular hospitalisation rates and associated costs in patients at risk of atherothrombosis in France and Germany: highest burden for peripheral arterial disease.
    Smolderen KG; Wang K; de Pouvourville G; Brüggenjürgen B; Röther J; Zeymer U; Parhofer KG; Steg PG; Bhatt DL; Magnuson EA;
    Eur J Vasc Endovasc Surg; 2012 Feb; 43(2):198-207. PubMed ID: 22001145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term cardiovascular outcome, use of resources, and healthcare costs in patients with peripheral artery disease: results from a nationwide Swedish study.
    Hasvold P; Nordanstig J; Kragsterman B; Kristensen T; Falkenberg M; Johansson S; Thuresson M; Sigvant B
    Eur Heart J Qual Care Clin Outcomes; 2018 Jan; 4(1):10-17. PubMed ID: 28950310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes and medical care costs among medicare beneficiaries receiving therapy for peripheral arterial disease.
    Jaff MR; Cahill KE; Yu AP; Birnbaum HG; Engelhart LM
    Ann Vasc Surg; 2010 Jul; 24(5):577-87. PubMed ID: 20579582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
    Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
    J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temporal trends in healthcare resource utilization and costs following acute myocardial infarction.
    Shiyovich A; Gilutz H; Arbelle JE; Greenberg D; Plakht Y
    Isr J Health Policy Res; 2020 Feb; 9(1):6. PubMed ID: 32051030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Costs of healthcare resource consumption after a myocardial infarction in France: An estimate from a medicoadministrative database (GSB)].
    Philippe F; Blin P; Bouée S; Laurendeau C; Torreton E; Gourmelin J; Velkovski-Rouyer M; Levy-Bachelot L; Steg G
    Ann Cardiol Angeiol (Paris); 2017 Apr; 66(2):74-80. PubMed ID: 28139200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One-year costs associated with cardiovascular disease in Canada: Insights from the REduction of Atherothrombosis for Continued Health (REACH) registry.
    Smolderen KG; Bell A; Lei Y; Cohen EA; Steg PG; Bhatt DL; Mahoney EM;
    Can J Cardiol; 2010 Oct; 26(8):297-305. PubMed ID: 20931098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. National health care costs of peripheral arterial disease in the Medicare population.
    Hirsch AT; Hartman L; Town RJ; Virnig BA
    Vasc Med; 2008 Aug; 13(3):209-15. PubMed ID: 18687757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resource Use and Costs up to Two Years Post Diagnosis Among Newly Diagnosed COPD Patients in the UK Primary Care Setting: A Retrospective Cohort Study.
    Punekar YS; Wurst K; Shukla A
    COPD; 2015 Jun; 12(3):267-75. PubMed ID: 25093809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.